Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075738 | 0.89 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL1648486 | 0.78 | GRM1 (0.50) | GRM1FFAR3 | |
| SCHEMBL6058438 | 0.78 | KMT2A (0.54) | MEN1KMT2A | |
| SCHEMBL9142496 | 0.78 | GRM1 (0.50) | GRM1FFAR3 | |
| SCHEMBL19766525 | 0.77 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL30937226 | 0.77 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL19639655 | 0.76 | MEN1 (0.32) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27190969 | 0.75 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL12858008 | 0.75 | PKM (0.52) | MEN1KMT2A | |
| SCHEMBL19639616 | 0.75 | SMN1; SMN2 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | claimed |
| US-12049460-B2 | EGFR inhibitor compounds | RECURIUM IP HOLDINGS, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3464275-B1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-23 | — | — | US | disclosed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | disclosed |
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | GRM1 2187/4885MEN1 2877/4885KMT2A 3296/4885 |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, AMPD2 | GRM1 1666/4885MEN1 2653/4885KMT2A 3978/4885 |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | GRM1 2187/4885MEN1 2877/4885KMT2A 3296/4885 |
| US-12049460-B2 | EGFR inhibitor compounds | EGFR, ERBB2, ERBB3 | GRM1 1989/4885MEN1 1932/4885KMT2A 3178/4885 |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | GRM1 2187/4885MEN1 2877/4885KMT2A 3296/4885 |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, AMPD2 | GRM1 1666/4885MEN1 2653/4885KMT2A 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.